GE HealthCare Technologies Inc. (GEHC) is listed on NASDAQ and operates in the Medical - Healthcare Information Services industry (Healthcare sector).
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patie...
| Rating | Analysts |
|---|---|
| Strong Buy | 0 |
| Buy | 10 |
| Hold | 7 |
| Sell | 1 |
| Strong Sell | 0 |
GE HealthCare Technologies Inc., established in 2022 and headquartered in Chicago, Illinois, specializes in developing, manufacturing, and marketing healthcare products, services, and digital solutions. The company operates globally, including in the United States, Canada, Europe, the Middle East, Africa, and Asia. It is structured into four main segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.
The Imaging segment provides molecular imaging, computed tomography (CT), magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, along with women's health products. The Ultrasound segment offers solutions for screening, diagnosis, treatment, and monitoring in radiology, primary care, women's health, cardiovascular, and point-of-care settings, including surgical visualization products. Patient Care Solutions delivers medical devices, consumables, and digital solutions for patient monitoring, anesthesia delivery, respiratory care, diagnostic cardiology, and maternal infant care. The Pharmaceutical Diagnostics segment supplies diagnostic agents and contrast media pharmaceuticals for enhanced imaging visibility, as well as molecular imaging agents used in radiology and nuclear medicine.
Over the past three fiscal years, the company has demonstrated a consistent increase in revenue, growing at a 2.7% CAGR from $19.55 billion in 2023 to $20.63 billion in 2025. This revenue growth has been accompanied by a significant improvement in earnings per share (EPS), which increased at a robust 22.7% CAGR, rising from $3.02 to $4.55. Operating margins have also improved, expanding by 0.9 percentage points from 12.5% to 13.4%, indicating effective cost management and operational efficiency. However, gross margins showed some inconsistency, slightly compressing by 0.5 percentage points, which may suggest rising production costs or pricing pressures. Despite the positive revenue and EPS trends, free cash flow (FCF) has consistently decreased, with a 6.3% annual decline, dropping from $1.71 billion to $1.51 billion, and the FCF margin contracted by 1.5 percentage points. This decline in FCF, alongside a consistent decrease in cash conversion ratio (CCR) to 0.92, suggests that cash generation is not keeping pace with accounting earnings. On the capital efficiency front, net debt has decreased significantly by 13.6% annually, reducing from $7.36 billion to $5.49 billion, which strengthens the company's balance sheet. Interest coverage has improved to 7.1x, reflecting a stronger ability to meet interest obligations. Overall, while the company has shown strong revenue and EPS growth, the decline in cash flow metrics and slight gross margin compression warrant close attention.
In recent developments for GE HealthCare Technologies (GEHC), the company has been highlighted for its earnings growth and price strength, making it a stock to watch according to Zacks Investment Research as of April 20, 2026. Analyst ratings have shown mixed sentiment, with a consensus "Hold" rating. Notably, Citigroup decreased its price target to $88, while Evercore and Stifel Nicolaus raised their targets to $95. On the strategic front, GE HealthCare announced a digital integration between its bkActiv™ intraoperative ultrasound system and Medtronic's Stealth AXiS™ surgical navigation system on April 9, 2026. Additionally, the company expanded its collaboration with RadNet's DeepHealth to enhance global access to AI-powered breast cancer screening solutions as of April 16, 2026. In terms of trading activity, Asio Capital LLC reduced its position in GE HealthCare by 9% in the fourth quarter, while Acadian Asset Management LLC acquired a new stake valued at approximately $259,000 in the first quarter. These developments reflect ongoing strategic initiatives and varied investor sentiment, with trading activities suggesting routine portfolio adjustments rather than significant shifts in company outlook.